SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-22-025753
Filing Date
2022-05-12
Accepted
2022-05-12 09:01:56
Documents
14
Period of Report
2022-05-12
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea159808-8k_unicycive.htm   iXBRL 8-K 37566
2 PRESS RELEASE OF UNICYCIVE THERAPEUTICS, INC. DATED MAY 12, 2022 ea159808ex99-1_unicycive.htm EX-99.1 52893
6 GRAPHIC ex99-1_001.jpg GRAPHIC 3435
  Complete submission text file 0001213900-22-025753.txt   278366

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE uncy-20220512.xsd EX-101.SCH 3036
4 XBRL LABEL FILE uncy-20220512_lab.xml EX-101.LAB 34476
5 XBRL PRESENTATION FILE uncy-20220512_pre.xml EX-101.PRE 22597
8 EXTRACTED XBRL INSTANCE DOCUMENT ea159808-8k_unicycive_htm.xml XML 3715
Mailing Address 4300 EL CAMINO REAL, SUITE 210 LOS ALTOS CA 94022
Business Address 4300 EL CAMINO REAL, SUITE 210 LOS ALTOS CA 94022 650-384-0642
Unicycive Therapeutics, Inc. (Filer) CIK: 0001766140 (see all company filings)

IRS No.: 813638692 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40582 | Film No.: 22915943
SIC: 2834 Pharmaceutical Preparations